Novartis (NVS) reported $13.34 billion in revenue for the quarter ended December 2025, representing a year-over-year increase of 1.4%. EPS of $2.03 for the same period compares to $1.98 a year ago.
The reported revenue represents a surprise of -2.67% over the Zacks Consensus Estimate of $13.7 billion. With the consensus EPS estimate being $1.99, the EPS surprise was +2.14%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Novartis performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Immunology- Ilaris- US: $294 million versus the three-analyst average estimate of $284.6 million. The reported number represents a year-over-year change of +26.2%.
- Revenues- Immunology- Ilaris- ROW: $220 million versus the three-analyst average estimate of $212.16 million. The reported number represents a year-over-year change of +22.2%.
- Revenues- Established Brands- Exforge Group- ROW: $180 million versus the three-analyst average estimate of $160.03 million. The reported number represents a year-over-year change of +14.7%.
- Revenues- Established Brands- Diovan Group- US: $8 million compared to the $7.04 million average estimate based on three analysts. The reported number represents a change of +14.3% year over year.
- Revenues- Oncology- Tafinlar + Mekinist- Total: $540 million compared to the $538.87 million average estimate based on three analysts. The reported number represents a change of +2.5% year over year.
- Revenues- Net sales to third parties: $13.34 billion versus the three-analyst average estimate of $13.7 billion. The reported number represents a year-over-year change of +1.4%.
- Revenues- Oncology- Kisqali- Total: $1.32 billion versus $1.49 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +46.5% change.
- Revenues- Immunology- Cosentyx- Total: $1.81 billion versus $1.66 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +13.2% change.
- Revenues- Cardiovascular- Entresto- Total: $1.25 billion versus $1.54 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -42.5% change.
- Revenues- Established Brands- Galvus Group- Total: $114 million versus $126.48 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -20.8% change.
- Revenues- Established Brands- Exforge Group- Total: $181 million versus $162.86 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +13.8% change.
- Revenues- Established brands- Kymriah- Total: $85 million compared to the $95.24 million average estimate based on three analysts. The reported number represents a change of -21.3% year over year.
View all Key Company Metrics for Novartis here>>>
Shares of Novartis have returned +5.3% over the past month versus the Zacks S&P 500 composite's +0.9% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Novartis AG (NVS): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
